Transplanted sickle‐cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary. Bone marrow transplantation (BMT) is the only curative therapy for sickle‐cell disease (SCD), but is not devoid of failure risk. Nine patients with severe SCD were grafted in our institution between 1988 and 1993. Six patients successfully engrafted, but three failed to engraft and had delayed autologous recovery. All patients had, prior to BMT, low levels of fetal haemoglobin (HbF ≤3.5%). No change in HbF occurred in successfully grafted patients. In the three patients with graft failure HbF increased and remained persistently present at a high level (≥22%) 14 months, 16 months and 39 months post BMT, although two of the three patients were homozygous for either the Benin or the Central African Republic haplotype, a characteristic associated with low HbF level. Of interest, these three previously severely affected patients remain free of vaso‐occlusive events. The mechanism responsible for the expression of high levels of HbF in our three patients with graft failure is not understood, but it protects them from the recurrence of severe vaso‐occlusive crises.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+Thalassemia
Ley, T. J., DeSimone, J., Anagnou, N. P., Keller, G. H., Humphries, R. K., Turner, P. H., Young, N. S., Heller, P., & Nienhuis, A. W. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212093072401 · Cited by 490
5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.
DeSimone, J., Heller, P., Hall, L., & Zwiers, D. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.14.4428 · Cited by 384
Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?
Powars, D., Weiss, J., Chan, L., & Schroeder, W. (1984) · Blood · doi:10.1182/blood.v63.4.921.921 · Cited by 314
Natural History of Sickle Cell Anemia in Saudi Arabs: A Study of 270 Subjects
PERRINE, R. P., PEMBREY, M. E., JOHN, P., PERRINE, S., & SHOUP, F. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-1-1 · Cited by 284
Levels of Fetal Hemoglobin Necessary for Treatment of Sickle Cell Disease
Noguchi, C. T., Rodgers, G. P., Serjeant, G., & Schechter, A. N. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180207 · Cited by 222
Cited by
Vermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhooge, C., Benoit, Y., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701291 · Cited by 260
Self-citationHematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia
Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011825 · Cited by 166
Kanter, J., Thompson, A. A., Pierciey, F. J., Hsieh, M., Uchida, N., Leboulch, P., Schmidt, M., Bonner, M., Guo, R., Miller, A., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26741 · Cited by 134
Metadata
- Authors
- FERSTER, A., CORAZZA, F., VERTONGEN, F., BUJAN, W., DEVALCK, C., FONDU, P., COCHAUX, P., LAMBERMONT, M., KHALADJI, Z., & SARIBAN, E.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 1995-08
- Volume
- 90
- Issue
- 4
- Pages
- 804-808
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2129959223
- Cited by
- 36
- References
- 6
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transplanted sickle‐cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity. https://app.cochat.ai/papers/10.1111/j.1365-2141.1995.tb05199.x
- The paper
- FERSTER, A., CORAZZA, F., VERTONGEN, F., BUJAN, W., DEVALCK, C., FONDU, P., COCHAUX, P., LAMBERMONT, M., KHALADJI, Z., & SARIBAN, E. (1995). Transplanted sickle‐cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.1995.tb05199.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.